logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer Says Xarelto Proven Effective In Treating Patients With Pulmonary Embolism

Bayer HealthCare, a subgroup of Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said that the oral anticoagulant Xarelto, or rivaroxaban, used as a single drug intervention, was as effective and safe as the current dual drug approach of subcutaneous enoxaparin followed by Vitamin K antagonist, in treating patients with acute symptomatic pulmonary embolism and preventing them from developing a secondary venous blood clot.

Rivaroxaban showed similar overall bleeding rates, but was associated with significantly lower rates of major bleeding versus the current standard of care.

The company noted that Rivaroxaban was also proven effective in preventing recurrent venous blood clots in Phase III EINSTEIN-PE Study.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Best Buy Co., Inc. (BBY) reported first-quarter non-GAAP earnings per share from continuing operations of $0.44, an increase of 19% from $0.37, a year ago. On average, 21 analysts polled by Thomson Reuters expected the company to report profit per share of $0.35 for the quarter. Analysts' estimates typically... Automotive parts retailer AutoZone, Inc. on Tuesday reported a 6 percent increase in profit for the third quarter from last year, reflecting growth in sales and higher inventory on new store openings. However, both revenue and earnings per share for the quarter missed analysts' expectations. Toll Brothers, Inc. (TOL), the nation's leading builder of luxury homes, reported second-quarter net income of $89.1 million, or $0.51 per share, compared to $67.9 million, or $0.37 per share, prior year. Pre-tax income increased to $140.4 million from $86.5 million. On average, 18 analysts polled by...
comments powered by Disqus
Follow RTT